Download PDF
Aktuelle Urol 2023; 54(05): 398-404
DOI: 10.1055/a-2002-7750
Übersicht

Prostatakarzinom: Nebenwirkungsmanagement unter Androgendeprivationstherapie

Prostate Cancer: Side-Effect Management for Androgen Deprivation Therapy
Eva Hellmis
1   Urologie, Urologicum Duisburg, Duisburg, Deutschland
,
Tobias Niels Mudra
2   Städtisches Klinikum Dresden, Dresden, Deutschland (Ringgold ID: RIN533434)
,
Axel S. Merseburger
3   Urologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Deutschland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Die medikamentöse Hormonablation ist beim fortgeschrittenen hormonsensitiven Prostatakarzinom und als Backbone in der Kastrationsresistenz ein essenzieller Therapiebaustein. LHRH-Agonisten gehören zu den am häufigsten eingesetzten Präparaten. Da diese in der Regel lebenslang gegeben werden, kommt dem Therapiemanagement eine besondere Bedeutung zu. Klassentypische häufige Nebenwirkungen wie Gewichtszunahme, kardiovaskuläre Probleme, Hitzewallungen, erektile Dysfunktion oder Osteoporose können die Lebensqualität der Patienten erheblich einschränken und zu erhöhter Morbidität und Mortalität führen. Dies gefährdet die Adhärenz und damit auch den Therapieerfolg. Die vorliegende Arbeit gibt einen Überblick zum Umgang mit Nebenwirkungen unter einer Androgendeprivationstherapie auf der Basis aktueller Daten und praktischer Erfahrungen.

Abstract

Drug-based hormonal ablation is an essential component of therapy in hormone-sensitive advanced prostate cancer and as a backbone in castration resistance. LHRH agonists are among the most widely used medicinal products. Since these are usually given for life, therapy management is very important. Common side-effects typical of the substance class, such as weight gain, cardiovascular problems, hot flushes, erectile dysfunction or osteoporosis, can significantly reduce patients’ quality of life and increase morbidity and mortality. This endangers adherence and, hence, treatment success. This paper provides an overview of how to deal with side-effects during LHRH therapy based on current data and practical experience.

Schlüsselwörter

Prostatakarzinom - hormonsensitiv - Androgendeprivation - Nebenwirkungsmanagement

Keywords

ADT - side-effect management - prostate cancer - hormone-sensitive


Publication History

Received: 14 December 2021

Accepted after revision: 14 December 2022

Article published online:
27 March 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 6.0, 2021, AWMF Registernummer: 043/022OL. Accessed November 02, 2021 at: http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/
    PubMed
  • 2 Hupe MC, Hammerer P, Ketz M. et al. Retrospective SHI (Statutory Health Insurances) real-world study on initial GnRH antagonist and agonist therapy for advanced prostate cancer: prescription patterns and hospital costs in Germany. Aktuelle Urol 2020; 51: 275-284
    Thieme ConnectPubMedSearch in Google Scholar
  • 3 Cook T, Sheridan WP. Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist 2000; 5: 162-168
    CrossrefPubMedSearch in Google Scholar
  • 4 Hammerer P, Grohmann W, Merseburger AS. Current data on the target value of testosterone lowering and the associated research since the first administration of LHRH (GnRH) analogues to patients 40 years ago. Aktuelle Urol 2020; 51: 552-556
    Thieme ConnectPubMedSearch in Google Scholar
  • 5 Klotz L, O'Callaghan C, Ding K. et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol 2015; 33: 1151-1156
    CrossrefPubMedSearch in Google Scholar
  • 6 Mottet N, Cornford P, Van den Bergh E. et al. EAU Guideline Prostate Cancer. Accessed August 23, 2021 at: https://uroweb.org/guideline/prostate-cancer/
    PubMed
  • 7 Zastrow S, Mudra TN, Suttmann H. Management of testosterone in advanced hormone-sensitive prostate cancer: still up to date?. Aktuelle Urol 2022; 53: 37-42
    Thieme ConnectPubMedSearch in Google Scholar
  • 8 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Supportive Therapie bei onkologischen PatientInnen - Langversion 1.3, 2020, AWMF Registernummer: 032/054OL. Accessed August 26, 2021 at: https://www.leitlinienprogramm-onkologie.de/leitlinien/supportive-therapie
    PubMed
  • 9 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Komplementärmedizin in der Behandlung von onkologischen PatientInnen, Langversion 1.0, 2021, AWMF Registernummer: 032/055OL. Accessed August 24, 2021 at: https://www.leitlinienprogramm-onkologie.de/leitlinien/komplementaermedizin/
    PubMed
  • 10 Kokorovic A, So AI, Serag H. et al. Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies. Can Urol Assoc J 2021; 15: E307-e322
    CrossrefPubMedSearch in Google Scholar
  • 11 Elghazaly H, Mottet N, Garcia J. et al. Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts. World J Urol 2021; 39: 1421-1429
    CrossrefPubMedSearch in Google Scholar
  • 12 Dueregger A, Heidegger I, Ofer P. et al. The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment. Nutrients 2014; 6: 4491-4519
    CrossrefPubMedSearch in Google Scholar
  • 13 Mohile SG, Mustian K, Bylow K. et al. Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol 2009; 70: 235-255
    CrossrefPubMedSearch in Google Scholar
  • 14 Shore ND, Antonarakis ES, Cookson MS. et al. Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines. Prostate 2020; 80: 527-544
    CrossrefPubMedSearch in Google Scholar
  • 15 von Amsberg G, Thiele H, Merseburger A. Cardiovascular side effects in patients undergoing androgen deprivation therapy: superiority of gonadotropin-releasing hormone antagonists? An update. Urologe A 2021; 60: 1450-1457
    CrossrefPubMedSearch in Google Scholar
  • 16 Shore ND, Saad F, Cookson MS. et al. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020; 382: 2187-2196
    CrossrefPubMedSearch in Google Scholar
  • 17 Lopes RD, Higano CS, Slovin SF. et al. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. Circulation 2021; 144: 1295-1307
    CrossrefPubMedSearch in Google Scholar
  • 18 Hamilton RJ, Ding K, Crook JM. et al. The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. Eur Urol 2021; 79: 446-452
    CrossrefPubMedSearch in Google Scholar
  • 19 Moyad MA, Newton RU, Tunn UW. et al. Integrating diet and exercise into care of prostate cancer patients on androgen deprivation therapy. Res Rep Urol 2016; 8: 133-143
    CrossrefPubMedSearch in Google Scholar
  • 20 White ID, Wilson J, Aslet P. et al. Development of UK guidance on the management of erectile dysfunction resulting from radical radiotherapy and androgen deprivation therapy for prostate cancer. Int J Clin Pract 2015; 69: 106-123
    CrossrefPubMedSearch in Google Scholar
  • 21 Pressemitteilung G-BA: Kryokonservierung von Ei- und Samenzellen als GKV-Leistung. Accessed August 25, 2021 at: https://www.g-ba.de/presse/pressemitteilungen-meldungen/878/
    PubMed
  • 22 Shahinian VB, Kuo YF, Freeman JL. et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-164
    CrossrefPubMedSearch in Google Scholar
  • 23 Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und bei Männern, AWMF-Registernr. 183/001; 2017. Accessed August 24, 2021 at: https://www.awmf.org/uploads/tx_szleitlinien/183–001l_S3_Osteoporose-Prophylaxe-Diagnostik-Therapie_2019–02.pdf
    PubMed
  • 24 Hupe MC, Müller M, Struck JP. et al. Osteoprotection in the management of metastatic prostate cancer: real-world data from Germany and decision guidance. Aktuelle Urol 2022; 53: 43-53
    Thieme ConnectPubMedSearch in Google Scholar
  • 25 Fachinformation Prolia; Stand: September 2020.
    PubMed
  • 26 Smith MR, Egerdie B, Hernández Toriz N. et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-755
    CrossrefPubMedSearch in Google Scholar
  • 27 Elbourne H, Soo WK, O'Reilly V. et al. Exercise as a supportive care strategy in men with prostate cancer receiving androgen deprivation therapy at a regional cancer centre: a survey of patients and clinicians. Support Care Cancer 2022; 30: 1379-1389
    CrossrefPubMedSearch in Google Scholar
  • 28 Baumann FT, Zopf EM, Bloch W. Clinical exercise interventions in prostate cancer patients--a systematic review of randomized controlled trials. Support Care Cancer 2012; 20: 221-233
    CrossrefPubMedSearch in Google Scholar
  • 29 Sari Motlagh R, Quhal F, Mori K. et al. The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. J Urol 2021; 205: 60-67
    CrossrefPubMedSearch in Google Scholar
  • 30 Kim JW, Kim DK, Lee HS. et al. Androgen Deprivation Therapy in Patients with Prostate Cancer is Associated with the Risk of Subsequent Alzheimer's Disease but not with Vascular Dementia. World J Mens Health 2022; 40: 481-489
    CrossrefPubMedSearch in Google Scholar
  • 31 Liu JM, Shen CY, Lau WCY. et al. Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer. Cancers (Basel) 2021; 13 (15) 3861
    CrossrefPubMedSearch in Google Scholar
  • 32 Shim M, Bang WJ, Oh CY. et al. Risk of dementia and Parkinson's disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study. PLoS One 2020; 15: e0244660
    CrossrefPubMedSearch in Google Scholar
  • 33 Shin D, Shim SR, Kim CH. Changes in Beck Depression Inventory scores in prostate cancer patients undergoing androgen deprivation therapy or prostatectomy. PLoS One 2020; 15: e0234264
    CrossrefPubMedSearch in Google Scholar
  • 34 Casey RG, Corcoran NM, Goldenberg SL. Quality of life issues in men undergoing androgen deprivation therapy: a review. Asian J Androl 2012; 14: 226-231
    CrossrefPubMedSearch in Google Scholar
  • 35 DGPPN, BÄK, KBV. et al. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression, 2. Auflage. Version 1. 2017 Accessed August 24, 2021 at: https://www.depression.versorgungsleitlinien.de
    PubMedSearch in Google Scholar
  • 36 Yasukawa K, Sawamura D, Sugawara H. et al. Leuprorelin acetate granulomas: case reports and review of the literature. Br J Dermatol 2005; 152: 1045-1047
    CrossrefPubMedSearch in Google Scholar
  • 37 Haensch CA, Hilz M, Jost W. et al. S1-Guideline for Diagnosis and Treatment of Erectile Dysfunction. Fortschr Neurol Psychiatr 2019; 87: 225-233
    Thieme ConnectPubMedSearch in Google Scholar